Melatonin and its analog 5-methoxycarbonylamino-N-acetyltryptamine potentiate adrenergic receptor-mediated ocular hypotensive effects in rabbits: Significance for combination therapy in glaucoma

Journal of Pharmacology and Experimental Therapeutics

Volumn 346, Issue 1, 2013, Pages 138-145

  Crooke, Almudena ^a   Huete Toral, Fernando ^a   Martínez Águila, Alejandro ^a   Martín Gil, Alba ^a   Pintor, Jesús ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

5 METHOXYCARBONYLAMINO N ACETYLTRYPTAMINE; ALPHA 2A ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; BRIMONIDINE; MELATONIN; MELATONIN DERIVATIVE; MESSENGER RNA; TIMOLOL; TIMOLOL MALEATE; UNCLASSIFIED DRUG;

ADRA2A GENE; ADRAB2 GENE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CILIATED EPITHELIUM; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; GENE; GENE EXPRESSION REGULATION; GLAUCOMA; IMMUNOCYTOCHEMISTRY; IN VITRO STUDY; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MALE; MONOTHERAPY; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RABBIT; TREATMENT OUTCOME;

ADRENERGIC AGONISTS; ADRENERGIC ALPHA-2 RECEPTOR AGONISTS; ADRENERGIC BETA-ANTAGONISTS; ANIMALS; CELLS, CULTURED; CILIARY BODY; DRUG SYNERGISM; EPITHELIAL CELLS; GENE EXPRESSION REGULATION; GLAUCOMA; INTRAOCULAR PRESSURE; MALE; MELATONIN; NERVE TISSUE PROTEINS; NEUROPROTECTIVE AGENTS; OCULAR HYPOTENSION; OPHTHALMIC SOLUTIONS; RABBITS; RECEPTORS, ADRENERGIC, ALPHA-2; RECEPTORS, ADRENERGIC, BETA-2; TRYPTAMINES;

EID: 84879301307     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.112.202036     Document Type: Article

References (67)

1. Adkins JC and Balfour JA (1998) Brimonidine. A review of its pharmacological properties and clinical potential in the management of open-angle glaucoma and ocular hypertension. Drugs Aging 12:225-241.
2. Agorastos A and Huber CG (2011) The role of melatonin in glaucoma: implications concerning pathophysiological relevance and therapeutic potential. J Pineal Res 50:1-7.
3. Akman A, Cetinkaya A, Akova Y.A., and Ertan A (2005) Comparison of additional intraocular pressure-lowering effects of latanoprost vs brimonidine in primary open-angle glaucoma patients with intraocular pressure uncontrolled by timolol-dorzolamide combination. Eye (Lond) 19:145-151.
4. Alarma-Estrany P., Crooke A, Peral A., and Pintor J (2007) Requirement of intact sympathetic transmission for the ocular hypotensive effects of melatonin and 5-MCA-NAT. Auton Neurosci 137:63-66.
5. Alarma-Estrany P., Crooke A, and Pintor J (2009) 5-MCA-NAT does not act through NQO2 to reduce intraocular pressure in New-Zealand white rabbit. J Pineal Res 47:201-209.
6. Alarma-Estrany P., Guzman-Aranguez A, Huete F., Peral A, Plourde R, Jr, Pelaez T, Yerxa B, and Pintor J (2011) Design of novel melatonin analogs for the reduction of intraocular pressure in normotensive rabbits. J Pharmacol Exp Ther 337:703-709.
7. Alarma-Estrany P.C., Crooke A, Mediero A., Peláez T, and Pintor J (2008) Sympathetic nervous system modulates the ocular hypotensive action of MT2-melatonin receptors in normotensive rabbits. J Pineal Res 45:468-475.
8. Alm A and Nilsson SF (2009) Uveoscleral outflow - a review. Exp Eye Res 88: 760-768.
9. Almasieh M, Wilson AM, Morquette B, Cueva Vargas JL, and Di Polo A (2012) The molecular basis of retinal ganglion cell death in glaucoma. Prog Retin Eye Res 31: 152-181.
10. Anisimov SV and Popovic N (2004) Genetic aspects of melatonin biology. Rev Neurosci 15:209-230.
11. Bartels SP, Roth HO, Jumblatt M.M., and Neufeld AH (1980) Pharmacological effects of topical timolol in the rabbit eye. Invest Ophthalmol Vis Sci 19:1189-1197.
12. Belforte NA, Moreno MC, de Zavalía N, Sande PH, Chianelli MS, Keller Sarmiento MI, and Rosenstein RE (2010) Melatonin: a novel neuroprotectant for the treatment of glaucoma. J Pineal Res 48:353-364.
13. Bengtsson T, Cannon B, and Nedergaard J (2000) Differential adrenergic regulation of the gene expression of the beta-adrenoceptor subtypes beta1, beta2 and beta3 in brown adipocytes. Biochem J 347:643-651.
14. Civan MM and Macknight AD (2004) The ins and outs of aqueous humour secretion. Exp Eye Res 78:625-631.
15. Collins TJ (2007) ImageJ for microscopy. Biotechniques 43(1, suppl)25-30.
16. Coon SL, McCune SK, Sugden D, and Klein DC (1997) Regulation of pineal alpha1B-adrenergic receptor mRNA: day/night rhythm and beta-adrenergic receptor/cyclic AMP control. Mol Pharmacol 51:551-557.
17. Cordeiro MF and Levin LA (2011) Clinical evidence for neuroprotection in glaucoma. Am J Ophthalmol 152:715-716.
18. Crider JY and Sharif NA (2002) Adenylyl cyclase activity mediated by beta-adrenoceptors in immortalized human trabecular meshwork and non-pigmented ciliary epithelial cells. J Ocul Pharmacol Ther 18:221-230.
19. Crooke A, Colligris B, and Pintor J (2012a) Update in glaucoma medicinal chemistry: emerging evidence for the importance of melatonin analogues. Curr Med Chem 19: 3508-3522.
20. Crooke A, Huete-Toral F, Martínez-Águila A, Alarma-Estrany P, and Pintor J (2011) Regulation of ocular adrenoceptor genes expression by 5-MCA-NAT: implications for glaucoma treatment. Pharmacogenet Genomics 21:587-589.
21. Crooke A, Huete-Toral F, Martínez-Águila A, Martín-Gil A, and Pintor J (2012b) Involvement of carbonic anhydrases in the ocular hypotensive effect of melatonin analogue 5-MCA-NAT. J Pineal Res 52:265-270.
22. Dortch-Carnes J and Tosini G (2013) Melatonin receptor agonist-induced reduction of SNP-released nitric oxide and cGMP production in isolated human non-pigmented ciliary epithelial cells. Exp Eye Res 107:1-10.
23. Ferrer E (2006) Trabecular meshwork as a new target for the treatment of glaucoma. Drug News Perspect 19:151-158.
24. Fustin JM, Dardente H, Wagner G.C., Carter DA, Johnston JD, Lincoln GA, and Hazlerigg DG (2009) Egr1 involvement in evening gene regulation by melatonin. FASEB J 23:764-773.
25. Grewal D, Jain R, Brar G.S., and Grewal SP (2008) Pentacam tomograms: a novel method for quantification of posterior capsule opacification. Invest Ophthalmol Vis Sci 49:2004-2008.
26. Hartenbaum D, Maloney S, Vaccarelli L., Liss C, Wilson H, and Gormley GJ (1999) Comparison of dorzolamide and pilocarpine as adjunctive therapy in patients with open-angle glaucoma and ocular hypertension. Clin Ther 21:1533-1538.
27. Hutzelmann J, Owens S, Shedden A., Adamsons I, and Vargas E; International Clinical Equivalence Study Group (1998) Comparison of the safety and efficacy of the fixed combination of dorzolamide/timolol and the concomitant administration of dorzolamide and timolol: a clinical equivalence study. Br J Ophthalmol 82: 1249-1253.
28. Ismail SA and Mowafi HA (2009) Melatonin provides anxiolysis, enhances analgesia, decreases intraocular pressure, and promotes better operating conditions during cataract surgery under topical anesthesia. Anesth Analg 108:1146-1151.
29. Kałuzny J.J., Szaflik J, Czechowicz-Janicka K, Kałuzny J, Orzalkiewicz A., Zaleska A, Krajewska M, Stewart J.A., Leech JN, and Stewart WC (2003) Timolol 0.5%/ dorzolamide 2% fixed combination versus timolol 0.5%/pilocarpine 2% fixed combination in primary open-angle glaucoma or ocular hypertensive patients. Acta Ophthalmol Scand 81:349-354.
30. Korkmaz A, Rosales-Corral S, and Reiter RJ (2012) Gene regulation by melatonin linked to epigenetic phenomena. Gene 503:1-11.
31. Krupin T, Liebmann JM, Greenfield D.S., Ritch R., and Gardiner S; Low-Pressure Glaucoma Study Group (2011) A randomized trial of brimonidine versus timolol in preserving visual function: results from the Low-Pressure Glaucoma Treatment Study. Am J Ophthalmol 151:671-681.
32. Lyashkov AE, Juhaszova M, Dobrzynski H., Vinogradova TM, Maltsev VA, Juhasz O, Spurgeon H.A., Sollott SJ, and Lakatta EG (2007) Calcium cycling protein density and functional importance to automaticity of isolated sinoatrial nodal cells are independent of cell size. Circ Res 100:1723-1731.
33. Martinez-Aguila A., Fonseca B, Bergua A., and Pintor J (2013) Melatonin analogue agomelatine reduces rabbit's intraocular pressure in normotensive and hypertensive conditions. Eur J Pharmacol 701:213-217.
34. Mayo JC, Sainz RM, Antoli I, Herrera F., Martin V, and Rodriguez C (2002) Mela-tonin regulation of antioxidant enzyme gene expression. Cell Mol Life Sci 59: 1706-1713.
35. McLaren JW (2009) Measurement of aqueous humor flow. Exp Eye Res 88:641-647.
36. Monjo M, Rodríguez AM, Palou A., and Roca P (2003) Direct effects of testosterone, 17 beta-estradiol, and progesterone on adrenergic regulation in cultured brown adipocytes: potential mechanism for gender-dependent thermogenesis. Endocrinology 144:4923-4930.
37. Moreno MC, Sande P, Marcos H.A., de Zavalía N, Keller Sarmiento MI, and Rosenstein RE (2005) Effect of glaucoma on the retinal glutamate/glutamine cycle activity. FASEB J 19:1161-1162.
38. Nowak JZ and Zawilska JB (1998) Melatonin and its physiological and therapeutic properties. Pharm World Sci 20:18-27.
39. Orengo-Nania S., Landry T, Von Tress M, Silver LH, Weiner A, and Davis AA; Travoprost Study Group (2001) Evaluation of travoprost as adjunctive therapy in patients with uncontrolled intraocular pressure while using timolol 0.5%. Am J Ophthalmol 132:860-868.
40. Osborne NN and Chidlow G (1994) The presence of functional melatonin receptors in the iris-ciliary processes of the rabbit eye. Exp Eye Res 59:3-9.
41. Pascale A, Drago F, and Govoni S (2012) Protecting the retinal neurons from glaucoma: lowering ocular pressure is not enough. Pharmacol Res 66:19-32.
42. Pinar-Sueiro S., Urcola H, Rivas M.A., and Vecino E (2011) Prevention of retinal ganglion cell swelling by systemic brimonidine in a rat experimental glaucoma model. Clin Experiment Ophthalmol 39:799-807.
43. Pintor J (2009) Autonomic nervous system: ophthalmic control, in Encyclopedia of Neuroscience (Squire LR ed) pp 967-974, Academic Press, Oxford.
44. Pintor J, Martin L, Pelaez T., Hoyle CH, and Peral A (2001) Involvement of melatonin MT(3) receptors in the regulation of intraocular pressure in rabbits. Eur J Pharmacol 416:251-254.
45. Pintor J, Martinez-Aguila A, and Bergua A (2011), inventors. Use of melatonin analogues for the reduction of the intraocular pressure. International patent P201101173. 2011 Oct 28.
46. Pintor J, Peláez T, Hoyle C.H., and Peral A (2003) Ocular hypotensive effects of melatonin receptor agonists in the rabbit: further evidence for an MT3 receptor. Br J Pharmacol 138:831-836.
47. Quigley HA (2011) Glaucoma. Lancet 377:1367-1377.
48. Reis R, Queiroz CF, Santos L.C., Avila MP, and Magacho L (2006) A randomized, investigator-masked, 4-week study comparing timolol maleate 0.5%, brinzolamide 1%, and brimonidine tartrate 0.2% as adjunctive therapies to travoprost 0.004% in adults with primary open-angle glaucoma or ocular hypertension. Clin Ther 28: 552-559.
49. Reitsamer HA, Posey M, and Kiel JW (2006) Effects of a topical a2 adrenergic agonist on ciliary blood flow and aqueous production in rabbits. Exp Eye Res 82:405-415.
50. Rosenstein RE, Pandi-Perumal SR, Srinivasan V., Spence DW, Brown GM, and Cardinali DP (2010) Melatonin as a therapeutic tool in ophthalmology: implications for glaucoma and uveitis. J Pineal Res 49:1-13.
51. Rowland JM, Potter DE, and Reiter RJ (1981) Circadian rhythm in intraocular pressure: a rabbit model. Curr Eye Res 1:169-173.
52. Serle JB, Wang RF, Peterson W.M., Plourde R., and Yerxa BR (2004) Effect of 5-MCA-NAT, a putative melatonin MT3 receptor agonist, on intraocular pressure in glaucomatous monkey eyes. J Glaucoma 13:385-388.
53. Shahidullah M, Tamiya S, and Delamere NA (2007) Primary culture of porcine nonpigmented ciliary epithelium. Curr Eye Res 32:511-522.
54. Sharif NA, Xu SX, Crider J.Y., McLaughlin M., and Davis TL (2001) Levobetaxolol (Betaxon) and other beta-adrenergic antagonists: preclinical pharmacology, IOP-lowering activity and sites of action in human eyes. J Ocul Pharmacol Ther 17: 305-317.
55. Simmons ST; Alphagan/Trusopt Study Group (2001) Efficacy of brimonidine 0.2% and dorzolamide 2% as adjunctive therapy to beta-blockers in adult patients with glaucoma or ocular hypertension. Clin Ther 23:604-619.
56. Siu AW, Maldonado M, Sanchez-Hidalgo M, Tan D.X., and Reiter RJ (2006) Protective effects of melatonin in experimental free radical-related ocular diseases. J Pineal Res 40:101-109.
57. Siu AW, Reiter RJ, and To CH (1999) Pineal indoleamines and vitamin E reduce nitric oxide-induced lipid peroxidation in rat retinal homogenates. J Pineal Res 27:122-128.
58. Solish AM, DeLucca PT, Cassel D.A., Kolodny AH, Hustad CM, and Skobieranda F (2004) Dorzolamide/Timolol fixed combination versus concomitant administration of brimonidine and timolol in patients with elevated intraocular pressure: a 3-month comparison of efficacy, tolerability, and patient-reported measures. J Glaucoma 13:149-157.
59. Spasojevic N, Gavrilovic L, and Dronjak S (2011) Regulation of atrial catecholamine enzymes and adrenoceptor gene expression after chronic stress. Acta Physiol Hung 98:433-441.
60. Stewart WC, Day DG, Sharpe E.D., Dubiner HB, Holmes KT, and Stewart JA (1999) Efficacy and safety of timolol solution once daily vs timolol gel added to latano-prost. Am J Ophthalmol 128:692-696.
61. Vareilles P, Silverstone D, Plazonnet B., Le Douarec JC, Sears ML, and Stone CA (1977) Comparison of the effects of timolol and other adrenergic agents on intraocular pressure in the rabbit. Invest Ophthalmol Vis Sci 16:987-996.
62. Vincent L, Cohen W, Delagrange P., Boutin JA, and Nosjean O (2010) Molecular and cellular pharmacological properties of 5-methoxycarbonylamino-N- acetyltryptamine (MCA-NAT): a nonspecific MT3 ligand. J Pineal Res 48:222-229.
63. von Borstel R.W., Renshaw AA, and Wurtman RJ (1984) Adenosine strongly potentiates pressor responses to nicotine in rats. Proc Natl Acad Sci USA 81:5599-5603.
64. von Borstel R.W., Wurtman RJ, and Conlay LA (1983) Chronic caffeine consumption potentiates the hypotensive action of circulating adenosine. Life Sci 32:1151-1158.
65. Webers CA, Beckers HJ, Nuijts R.M., and Schouten JS (2008) Pharmacological management of primary open-angle glaucoma: second-line options and beyond. Drugs Aging 25:729-759.
66. Wheeler L, WoldeMussie E, and Lai R (2003) Role of alpha-2 agonists in neuroprotection. Surv Ophthalmol 48 (suppl 1):S47-S51.
67. Wiechmann AF and Wirsig-Wiechmann CR (2001) Melatonin receptor mRNA and protein expression in Xenopus laevis nonpigmented ciliary epithelial cells. Exp Eye Res 73:617-623.